In an apparent move to shed a non-core business, Merck & Co has decided that it no longer wants to run its own in-house capability for the contract manufacture of biologics, although it will still have access to the operations that it has built up in this sector.
Merck & Co offloads contract biomanufacturing ops to Fujifilm
In an apparent move to shed a non-core business, Merck & Co has decided that it no longer wants to run its own in-house capability for the contract manufacture of biologics, although it will still have access to the operations that it has built up in this sector.
More from Japan
More from Focus On Asia
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.